Latest Investigational Device Exemption Stories
MONMOUTH JUNCTION, N.J., Dec.
Breakthrough Surgical Sealant Designed to Help Reduce Anastomotic Leaks for Patients Undergoing Gastrointestinal Resections PITTSBURGH, Dec.
Based on the results of the trial's pre-specified interim analysis all control patients in the EF-14 phase III trial will be offered the opportunity to cross over to receive Tumor Treating Fields
ALISO VIEJO, Calif., Aug. 28, 2014 /PRNewswire/ -- Sequent Medical, Inc.
SAN JOSE, Calif., June 10, 2014 /PRNewswire/ -- Pulsar Vascular, the innovator and developer of the PulseRider®, a minimally invasive, aneurysm neck reconstruction device,
SINGAPORE, May 5, 2014 /PRNewswire/ -- Biosensors International Group, Ltd.
DUBLIN, April 10, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/t45c8d/fda_approval) has announced the addition of the "FDA Approval
Results provide significant support to advance i-FACTOR(TM) Peptide Enhanced Bone Graft for FDA regulatory review. WESTMINSTER, Colo., March 11, 2014 /PRNewswire/ -- Cerapedics, Inc.,
According to a recent study, the approval of drugs by the Food and Drug Administration (FDA) is based on widely varying clinical trials between 2005 and 2012.